OncoMatch/Clinical Trials/NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Is NCT04895709 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including BMS-986340 and BMS-936558-01 for cervical cancer.
Treatment: BMS-986340 · BMS-936558-01 · Docetaxel · Pumitamig — The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Cervical Cancer
Gastric Cancer
Esophageal Carcinoma
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Urothelial Carcinoma
Pancreatic Cancer
Melanoma
Ovarian Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care therapy — advanced/metastatic
Radiographically documented progressive disease on or after the most recent therapy. Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
Cannot have received: docetaxel for advanced/metastatic setting (docetaxel)
Exception: applies only to Part 1C, 2C and 2D
participants with prior docetaxel use for the advanced/metastatic setting will be excluded (except for Part 1C, 2C and 2D)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Community Cancer Institute · Clovis, California
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- University of Iowa · Iowa City, Iowa
- John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04895709 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior docetaxel for advanced/metastatic setting disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages